Secreted CLU is associated with the initiation of triple-negative breast cancer

References

• von Minckwitz G, Untch M, Nüesch E, Loibl S, Kaufmann M, Kümmel S, et al. Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials. Breast Cancer Res Treat 2011; 125:145 - 56; http://dx.doi.org/10.1007/s10549-010-1228-x; PMID: 21042932
   PubMed Web of Science ®Google Scholar
• Tischkowitz M, Brunet J-S, Bégin LR, Huntsman DG, Cheang MCU, Akslen LA, et al. Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer 2007; 7:134; http://dx.doi.org/10.1186/1471-2407-7-134; PMID: 17650314
   PubMed Web of Science ®Google Scholar
• Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 2007; 109:1721 - 8; http://dx.doi.org/10.1002/cncr.22618; PMID: 17387718
   PubMed Web of Science ®Google Scholar
• Takei H, Kurosumi M, Yoshida T, Hayashi Y, Higuchi T, Uchida S, et al. Neoadjuvant endocrine therapy of breast cancer: which patients would benefit and what are the advantages?. Breast Cancer 2011; 18:85 - 91; http://dx.doi.org/10.1007/s12282-010-0239-0; PMID: 21104350
   PubMed Web of Science ®Google Scholar
• Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 1998; 58:2825 - 31; PMID: 9661897
   PubMed Web of Science ®Google Scholar
• Pal SK, Childs BH, Pegram M. Triple negative breast cancer: unmet medical needs. Breast Cancer Res Treat 2011; 125:627 - 36; http://dx.doi.org/10.1007/s10549-010-1293-1; PMID: 21161370
   PubMed Web of Science ®Google Scholar
• Lund MJB, Butler EN, Bumpers HL, Okoli J, Rizzo M, Hatchett N, et al. High prevalence of triple-negative tumors in an urban cancer center. Cancer 2008; 113:608 - 15; http://dx.doi.org/10.1002/cncr.23569; PMID: 18484596
   PubMed Web of Science ®Google Scholar
• Yuan Z-Y, Wang S-S, Gao Y, Su Z-Y, Luo W-B, Guan Z-Z. Clinical characteristics and prognosis of triple-negative breast cancer: a report of 305 cases. Ai Zheng 2008; 27:561 - 5; PMID: 18570725
   PubMedGoogle Scholar
• Yin W-J, Lu J-S, Di G-H, Lin Y-P, Zhou L-H, Liu G-Y, et al. Clinicopathological features of the triple-negative tumors in Chinese breast cancer patients. Breast Cancer Res Treat 2009; 115:325 - 33; http://dx.doi.org/10.1007/s10549-008-0096-0; PMID: 18563552
   PubMed Web of Science ®Google Scholar
• Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med 2010; 363:1938 - 48; http://dx.doi.org/10.1056/NEJMra1001389; PMID: 21067385
   PubMed Web of Science ®Google Scholar
• De Laurentiis M, Cianniello D, Caputo R, Stanzione B, Arpino G, Cinieri S, et al. Treatment of triple negative breast cancer (TNBC): current options and future perspectives. Cancer Treat Rev 2010; 36:Suppl 3 S80 - 6; http://dx.doi.org/10.1016/S0305-7372(10)70025-6; PMID: 21129616
   PubMed Web of Science ®Google Scholar
• Santana-Davila R, Perez EA. Treatment options for patients with triple-negative breast cancer. J Hematol Oncol. 2010; 3:42; http://dx.doi.org/10.1186/1756-8722-3-42; PMID: 20979652
   PubMed Web of Science ®Google Scholar
• Rosenberg ME, Silkensen J. Clusterin: physiologic and pathophysiologic considerations. Int J Biochem Cell Biol 1995; 27:633 - 45; http://dx.doi.org/10.1016/1357-2725(95)00027-M; PMID: 7648419
   PubMed Web of Science ®Google Scholar
• Sallman DA, Chen X, Zhong B, Gilvary DL, Zhou J, Wei S, et al. Clusterin mediates TRAIL resistance in prostate tumor cells. Mol Cancer Ther 2007; 6:2938 - 47; http://dx.doi.org/10.1158/1535-7163.MCT-07-0345; PMID: 18025278
   PubMed Web of Science ®Google Scholar
• Caccamo AE, Scaltriti M, Caporali A, D’Arca D, Corti A, Corvetta D, et al. Ca2+ depletion induces nuclear clusterin, a novel effector of apoptosis in immortalized human prostate cells. Cell Death Differ 2005; 12:101 - 4; http://dx.doi.org/10.1038/sj.cdd.4401491; PMID: 15499376
   PubMed Web of Science ®Google Scholar
• Lakins JN, Poon S, Easterbrook-Smith SB, Carver JA, Tenniswood MPR, Wilson MR. Evidence that clusterin has discrete chaperone and ligand binding sites. Biochemistry 2002; 41:282 - 91; http://dx.doi.org/10.1021/bi0157666; PMID: 11772027
   PubMed Web of Science ®Google Scholar
• Zellweger T, Miyake H, July LV, Akbari M, Kiyama S, Gleave ME. Chemosensitization of human renal cell cancer using antisense oligonucleotides targeting the antiapoptotic gene clusterin. Neoplasia 2001; 3:360 - 7; http://dx.doi.org/10.1038/sj.neo.7900174; PMID: 11571636
   PubMed Web of Science ®Google Scholar
• Hara I, Miyake H, Gleave ME, Kamidono S. Introduction of clusterin gene into human renal cell carcinoma cells enhances their resistance to cytotoxic chemotherapy through inhibition of apoptosis both in vitro and in vivo. Jpn J Cancer Res 2001; 92:1220 - 4; http://dx.doi.org/10.1111/j.1349-7006.2001.tb02143.x; PMID: 11714447
   PubMedGoogle Scholar
• Rizzi F, Bettuzzi S. Targeting Clusterin in prostate cancer. J Physiol Pharmacol 2008; 59:Suppl 9 265 - 74; PMID: 19261985
   PubMed Web of Science ®Google Scholar
• Zhang S, Zhang D, Zhu Y, Guo H, Zhao X, Sun B. Clusterin expression and univariate analysis of overall survival in human breast cancer. Technol Cancer Res Treat 2006; 5:573 - 8; PMID: 17121433
   PubMed Web of Science ®Google Scholar
• Shannan B, Seifert M, Leskov K, Willis J, Boothman D, Tilgen W, et al. Challenge and promise: roles for clusterin in pathogenesis, progression and therapy of cancer. Cell Death Differ 2006; 13:12 - 9; http://dx.doi.org/10.1038/sj.cdd.4401779; PMID: 16179938
   PubMed Web of Science ®Google Scholar
• Redondo M, Villar E, Torres-Muñoz J, Tellez T, Morell M, Petito CK. Overexpression of clusterin in human breast carcinoma. Am J Pathol 2000; 157:393 - 9; http://dx.doi.org/10.1016/S0002-9440(10)64552-X; PMID: 10934144
   PubMed Web of Science ®Google Scholar
• Krüger S, Ola V, Fischer D, Feller AC, Friedrich M. Prognostic significance of clusterin immunoreactivity in breast cancer. Neoplasma 2007; 54:46 - 50; PMID: 17203891
   PubMed Web of Science ®Google Scholar
• Flanagan L, Whyte L, Chatterjee N, Tenniswood M. Effects of clusterin over-expression on metastatic progression and therapy in breast cancer. BMC Cancer 2010; 10:107; http://dx.doi.org/10.1186/1471-2407-10-107; PMID: 20307318
   PubMed Web of Science ®Google Scholar
• Sutton D, Kim S, Shuai X, Leskov K, Marques JT, Williams BRG, et al. Efficient suppression of secretory clusterin levels by polymer-siRNA nanocomplexes enhances ionizing radiation lethality in human MCF-7 breast cancer cells in vitro. Int J Nanomedicine 2006; 1:155 - 62; http://dx.doi.org/10.2147/nano.2006.1.2.155; PMID: 17722531
   PubMed Web of Science ®Google Scholar
• Sun B, Zhang S, Zhang D, Li Y, Zhao X, Luo Y, et al. Identification of metastasis-related proteins and their clinical relevance to triple-negative human breast cancer. Clin Cancer Res 2008; 14:7050 - 9; http://dx.doi.org/10.1158/1078-0432.CCR-08-0520; PMID: 18981002
   PubMed Web of Science ®Google Scholar
• Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011; 121; http://dx.doi.org/10.1172/JCI45014; PMID: 21633166
   PubMed Web of Science ®Google Scholar
• Rizzi F, Bettuzzi S. The clusterin paradigm in prostate and breast carcinogenesis. Endocr Relat Cancer 2010; 17:R1 - 17; http://dx.doi.org/10.1677/ERC-09-0140; PMID: 19903745
   PubMedGoogle Scholar
• Cappelletti V, Gariboldi M, De Cecco L, Toffanin S, Reid JF, Lusa L, et al. Patterns and changes in gene expression following neo-adjuvant anti-estrogen treatment in estrogen receptor-positive breast cancer. Endocr Relat Cancer 2008; 15:439 - 49; http://dx.doi.org/10.1677/ERC-07-0274; PMID: 18508997
   PubMed Web of Science ®Google Scholar
• Trougakos IP, Lourda M, Antonelou MH, Kletsas D, Gorgoulis VG, Papassideri IS, et al. Intracellular clusterin inhibits mitochondrial apoptosis by suppressing p53-activating stress signals and stabilizing the cytosolic Ku70-Bax protein complex. Clin Cancer Res 2009; 15:48 - 59; http://dx.doi.org/10.1158/1078-0432.CCR-08-1805; PMID: 19118032
   PubMed Web of Science ®Google Scholar
• Niu L, Zang J, Cai L, Li C, Cao H. Relationship of clusterin expression with Bax and p53 expression in non-small cell lung cancer. Zhongguo Fei Ai Za Zhi. 2007; 10:284 - 7; PMID: 21122294
   PubMedGoogle Scholar
• So A, Sinnemann S, Huntsman D, Fazli L, Gleave M. Knockdown of the cytoprotective chaperone, clusterin, chemosensitizes human breast cancer cells both in vitro and in vivo. Mol Cancer Ther 2005; 4:1837 - 49; http://dx.doi.org/10.1158/1535-7163.MCT-05-0178; PMID: 16373699
   PubMed Web of Science ®Google Scholar
• Chi KN, Hotte SJ, Yu EY, Tu D, Eigl BJ, Tannock I, et al. Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 2010; 28:4247 - 54; http://dx.doi.org/10.1200/JCO.2009.26.8771; PMID: 20733135
   PubMed Web of Science ®Google Scholar
• Chi KN, Eisenhauer E, Fazli L, Jones EC, Goldenberg SL, Powers J, et al. A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2’-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J Natl Cancer Inst 2005; 97:1287 - 96; http://dx.doi.org/10.1093/jnci/dji252; PMID: 16145049
   PubMed Web of Science ®Google Scholar
• Chi KN, Siu LL, Hirte H, Hotte SJ, Knox J, Kollmansberger C, et al. A phase I study of OGX-011, a 2’-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer. Clin Cancer Res 2008; 14:833 - 9; http://dx.doi.org/10.1158/1078-0432.CCR-07-1310; PMID: 18245546
   PubMed Web of Science ®Google Scholar
• Chia S, Dent S, Ellard S, Ellis PM, Vandenberg T, Gelmon K, et al. Phase II trial of OGX-011 in combination with docetaxel in metastatic breast cancer. Clin Cancer Res 2009; 15:708 - 13; http://dx.doi.org/10.1158/1078-0432.CCR-08-1159; PMID: 19147778
   PubMed Web of Science ®Google Scholar
• Zoubeidi A, Chi K, Gleave M. Targeting the cytoprotective chaperone, clusterin, for treatment of advanced cancer. Clin Cancer Res 2010; 16:1088 - 93; http://dx.doi.org/10.1158/1078-0432.CCR-09-2917; PMID: 20145158
   PubMed Web of Science ®Google Scholar